Oncology Archives - Page 3 of 5 - Corcept Therapeutics

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

February 11, 2023

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

February 10, 2023

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

February 9, 2023

Munster et al • 2022 • Clin Cancer Res OF1–OF11

Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

February 6, 2023

Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting

A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

February 5, 2023

Borazanci et al • 2022 • American Society of Clinical Oncology Annual Meeting

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

January 27, 2023

Lorusso et al. • 2021 • European Society for Medical Oncology (ESMO) Congress 2021

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

January 26, 2023

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

January 25, 2023

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

November 22, 2022

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

November 20, 2022

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)